{
    "2019-07-19": [
        [
            {
                "time": "2018-07-16",
                "original_text": "Top Research Reports for Abbott, Netflix & Philip Morris",
                "features": {
                    "keywords": [
                        "Abbott",
                        "Netflix",
                        "Philip Morris"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "entertainment",
                        "tobacco"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-17",
                "original_text": "Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus",
                "features": {
                    "keywords": [
                        "JNJ",
                        "NVS",
                        "Q2 Earnings",
                        "Pipeline",
                        "Regulatory Updates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-18",
                "original_text": "Novartis Posts Strong Earnings, but Is Mum on Sales of Its New Gene Therapy",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Strong Earnings",
                        "Gene Therapy"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-19",
                "original_text": "Gilead licensing three pre-clinical programs from Novartis",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Novartis",
                        "pre-clinical programs",
                        "licensing"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-20",
                "original_text": "Should You Go for the 'Easy Money' in Novartis?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Easy Money"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}